Literature DB >> 458557

Time course of carbamazepine self-induction.

P J McNamara, W A Colburn, M Gibaldi.   

Abstract

Carbamazepine concentrations in plasma during repetitive oral dosing were analyzed by means of a nonlinear, variable parameter, regression program (VARPARM) assuming dose-to-dose changes in the apparent elimination rate constant of the drug. There was evidence of significant self-induction of carbamazepine metabolism as early as 1 or 2 days after initiation of the multiple-dose study. Additional self-induction appears to occur after about 2 weeks of treatment. The time course of carbamazepine self-induction appears to be complex, discontinuous, and prolonged.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 458557     DOI： 10.1007/bf01059441

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


  7 in total

1.  Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses.

Authors:  A P Géradin; F V Abadie; J A Campestrini; W Theobald
Journal:  J Pharmacokinet Biopharm       Date:  1976-12

2.  Pharmacokinetic analysis of drug concentration data obtained during repetitive drug administration.

Authors:  W A Colburn; D Shen; M Gibaldi
Journal:  J Pharmacokinet Biopharm       Date:  1976-12

3.  Pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine.

Authors:  W H Pitlick; R H Levy; A S Tropin; J R Green
Journal:  J Pharm Sci       Date:  1976-03       Impact factor: 3.534

4.  Pharmacokinetic analysis of drug concentration data obtained during repetitive drug administration.

Authors:  W A Colburn; M Gibaldi
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

Review 5.  Metabolism and Pharmacolinetics of Carbamazepine.

Authors:  P L Morselli; A Frigerio
Journal:  Drug Metab Rev       Date:  1975       Impact factor: 4.518

6.  Distribution and elimination kinetics of carbamazepine in man.

Authors:  M D Rawlins; P Collste; L Bertilsson; L Palmér
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

7.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953
  7 in total
  3 in total

Review 1.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

2.  A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy.

Authors:  H C Doheny; M A Whittington; J G R Jefferys; P N Patsalos
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

3.  Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid.

Authors:  M Ucar; M Neuvonen; H Luurila; R Dahlqvist; P J Neuvonen; T Mjörndal
Journal:  Eur J Clin Pharmacol       Date:  2003-12-23       Impact factor: 2.953
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.